急性呼吸窘迫综合征中的吸入镇静:SESAR随机临床试验
SESAR为3期随机、开放标签、评估者盲法试验,2020年5月至2023年10月在37个法国ICU纳入687例早期中重度ARDS成人(PaO2/FiO2<150 mmHg且PEEP≥8 cmH2O),随机接受吸入七氟烷或静脉丙泊酚镇静最长7天。主要终点28天无呼吸机天数在七氟烷组为0.0天(IQR 0.0–11.9),丙泊酚组为0.0天(IQR 0.0–18.7),中位差-2.1天(95%CI -3.6至-0.7)。90天生存率七氟烷组47.1% vs 丙泊酚组55.7%(HR 1.31,95%CI 1.05–1.62)。七氟烷组7天死亡率更高(19.4% vs 13.5%,RR 1.44,95%CI 1.02–2.03),28天无ICU天数更少(中位0.0 vs 0.0天,中位差-2.5,95%CI -3.7至-1.4)。
要点
- 中重度ARDS(PaO2/FiO2<150 mmHg且PEEP≥8 cmH2O)成人中,七氟烷组28天无呼吸机天数中位0.0天(IQR 0.0–11.9)vs 丙泊酚组0.0天(IQR 0.0–18.7),中位差-2.1天(95%CI -3.6至-0.7)。
- 90天生存率七氟烷组47.1% vs 丙泊酚组55.7%,HR 1.31(95%CI 1.05–1.62)。
- 七氟烷组7天死亡率19.4% vs 丙泊酚组13.5%,RR 1.44(95%CI 1.02–2.03)。
- 28天无ICU天数七氟烷组中位0.0天(IQR 0.0–6.0)vs 丙泊酚组0.0天(IQR 0.0–15.0),中位差-2.5天(95%CI -3.7至-1.4)。
- 两组镇静总时长中位均为7天(IQR 4–7),提示差异并非由镇静时长不同所致。
适用人群与场景
- 早期中重度ARDS成人,定义为PaO2/FiO2<150 mmHg且PEEP≥8 cmH2O,需机械通气镇静。
- 研究在37个法国ICU进行,纳入年龄均值65岁(SD 12)、女性30%的人群。
诊断标准与关键阈值
- ARDS纳入标准:PaO2/FiO2<150 mmHg且PEEP≥8 cmH2O。
处置流程与药物剂量
- 干预组采用吸入七氟烷镇静策略,对照组采用静脉丙泊酚镇静策略,镇静最长7天。
- 两组镇静总时长中位均为7天(IQR 4–7)。
研究设计与关键结果
- 3期随机、开放标签、评估者盲法试验,2020年5月至2023年10月,37个法国ICU,687例随机(七氟烷346例、丙泊酚341例),随访90天。
- 主要终点28天无呼吸机天数:七氟烷组中位0.0天(IQR 0.0–11.9)vs 丙泊酚组0.0天(IQR 0.0–18.7),中位差-2.1天(95%CI -3.6至-0.7);标准化HR 0.76(95%CI 0.50–0.97)。
- 关键次要终点90天生存率:七氟烷组47.1% vs 丙泊酚组55.7%,HR 1.31(95%CI 1.05–1.62)。
- 4项次要结局中,七氟烷组7天死亡率19.4% vs 丙泊酚组13.5%,RR 1.44(95%CI 1.02–2.03);28天无ICU天数中位0.0天(IQR 0.0–6.0)vs 0.0天(IQR 0.0–15.0),中位差-2.5天(95%CI -3.7至-1.4)。
证据类型、等级与局限
- 证据类型:3期随机、开放标签、评估者盲法临床试验。
- 试验注册号:ClinicalTrials.gov NCT04235608。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在中重度ARDS机械通气成人中,与静脉丙泊酚镇静相比,吸入七氟烷镇静导致28天无呼吸机天数更少、90天生存率更低,作者结论不支持在该人群使用吸入七氟烷镇静替代丙泊酚。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Whether the use of inhaled or intravenous sedation affects outcomes differentially in mechanically ventilated adults with acute respiratory distress syndrome (ARDS) is unknown.
OBJECTIVE: To determine the efficacy and safety of inhaled sevoflurane compared with intravenous propofol for sedation in patients with ARDS.
DESIGN, SETTING, AND PARTICIPANTS: Phase 3 randomized, open-label, assessor-blinded clinical trial conducted from May 2020 to October 2023 with 90-day follow-up. Adults with early moderate to severe ARDS (defined by a ratio of Pao2 to the fraction of inspired oxygen of <150 mm Hg with a positive end-expiratory pressure of ≥8 cm H2O) were enrolled in 37 French intensive care units.
INTERVENTIONS: Patients were randomized to a strategy of inhaled sedation with sevoflurane (intervention group) or to a strategy of intravenous sedation with propofol (control group) for up to 7 days.
MAIN OUTCOMES AND MEASURES: The primary end point was the number of ventilator-free days at 28 days; the key secondary end point was 90-day survival.
RESULTS: Of 687 patients enrolled (mean [SD] age, 65 [12] years; 30% female), 346 were randomized to sevoflurane and 341 to propofol. The median total duration of sedation was 7 days (IQR, 4 to 7) in both groups. The number of ventilator-free days through day 28 was 0.0 days (IQR, 0.0 to 11.9) in the sevoflurane group and 0.0 days (IQR, 0.0 to 18.7) in the propofol group (median difference, -2.1 [95% CI, -3.6 to -0.7]; standardized hazard ratio, 0.76 [95% CI, 0.50 to 0.97]). The 90-day survival rates were 47.1% and 55.7% in the sevoflurane and propofol groups, respectively (hazard ratio, 1.31 [95% CI, 1.05 to 1.62]). Among 4 secondary outcomes, sevoflurane was associated with higher 7-day mortality (19.4% vs 13.5%, respectively; relative risk, 1.44 [95% CI, 1.02 to 2.03]) and fewer intensive care unit-free days through day 28 (median, 0.0 [IQR, 0.0 to 6.0] vs 0.0 [IQR, 0.0 to 15.0]; median difference, -2.5 [95% CI, -3.7 to -1.4]) compared with propofol.
CONCLUSIONS AND RELEVANCE: Among patients with moderate to severe ARDS, inhaled sedation with sevoflurane resulted in fewer ventilator-free days at day 28 and lower 90-day survival than sedation with propofol.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04235608.
参考来源
- Jabaudon M, Quenot JP, Badie J, et al. Inhaled Sedation in Acute Respiratory Distress Syndrome: The SESAR Randomized Clinical Trial. JAMA. 2025. PMID: 40098564. doi:10.1001/jama.2025.3169
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。